The damn word: cancer.A disease that still scares, with a huge incidence due to the aging of the population and that leads laboratories to intensify their efforts in novel therapies.As a consequence, these increasingly sophisticated and expensive antitumor drugs become those known as blockbusters (superventas) in industry jargon.But not only in this pathology is the largest income mine for companies.Autoimmune diseases and diabetes are added.A trend that will be reinforced in the future.
In an analysis of the best -selling drug of each of the 20 largest laboratories in the world, in five cases its medicine that provides more income is a cancer therapy.This is the case of the Swiss Pharmacist Roche, with Avastin (6,251 million euros, with data from the 2016 year).In the case of this company, it has found in its innovative oncological therapies (such as Mabthera and Herceptin) a huge source of resources.
The antitumoral Glivec also becomes the supervent (2,953 million) of Novartis;Velcade for Japanese Takeda, and Revlimid for Biopharmaceutics Celgene.Also, in this therapeutic area is the blockbuster that has grown the most last year, 400%, called opvido, an innovative immunooncology treatment manufactured by BMS.
The medication that most raises in the world is Humira, of the American Abbvie, specifically 9,272 million.It is intended for autoimmune diseases (rheumatoid arthritis, crohn disease or psoriasis, among others).It is also the case of Reicade (6,191 million) of Janssen, and Enbrel (5,301 million) of Amgen.
All these medications have their high price in common, as they are a large part of new biological medicines for hospital use.They are not even the best sold in units (honor that falls on genericians such as Paracetamol, omeprazole, ibuprofen ...) but the ones that provide the most income.
A study by the QUINTILESIMS consultant notes that precisely oncology, autoimmune diseases and diabetes will be the main growth engines for the pharmaceutical industry in the world.For example, the Oncology segment will grow at a rate of sanitary expenditure between 9% and 12% per year until 2021, to reach between 120,000 and 135,000 million worldwide.
Autoimmune disease numbers are even greater growth - between 11% and 14% annual - that will lead the market to a maximum of 90,000 million.In the pathology of diabetes, up to 110,000 million will reach, with an increase of between 8% and 11% in the next four years.
84,765 million euros in 2016 entered the 20 largest laboratories with their best -selling medications. "
In diabetes they have found precisely their MSD best -selling drugs (Januvia, 3,473 million);Sanofi (Lantus, 5,078 million);Lilly (Humalog, 2,460 million), and Novo Nordisk (Novo Rapid, 2,384 million).
The antiviral pattern for hepatitis C suffers a curious case of death by success.After treating and cured hundreds of thousands of patients, as in the case of the well -known Sovaldi de Gilead, its use has been drastically reduced.It is Harvoni's example, also of that same American pharmaceutical, which despite being the most used remedy against this pathology, last year reduced its sales by 34%, staying at 8,071 million.In fact, with that loss, the world's largest supervantic throne gave in 2016.
the case of Botox
Botox's aesthetic product, by Allergan, entered 2,476 million euros last year (growth of 41%).But its main sales already come from other areas, such as neurological and urological, for more than 1,000 million.
The world's largest laboratory, the American giant Pfizer counts inThe vaccine prevent its superventas against pneumonia, which contributed 5,082 million.His best known drug, Viagra, entered 1,394 million.
In the case of the manufacturer of the aspirin, Bayer, its highest sales arrive through the Xarelto anticoagulant (2,602 million).
